Track topics on Twitter Track topics that are important to you
ISNES, Belgium, Sept. 15, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will attend Asia Pacific Digestive Week (APDW) and will host a symposium at the Taiwan Digestive Disease Week (TDDW).
Volition's Vice President of Asia, Dr. Jasmine Kway, commented, "Asia is a very important market for Volition and we have made significant progress in the region since January of this year. Our meetings at APDW and TDDW will give us excellent opportunities to further our conversations and formalize our engagements with key individuals in the Asia Pacific region."
There is a growing aging population in many countries in Asia, with more than 40% of worldwide colorectal cancers occurring there. Volition has been developing its position in Asia since the beginning of 2017 and has generated encouraging responses from key opinion leaders (KOLs) in the region. The Asia Pacific region would benefit greatly from a blood-based cancer test which is accurate, non-invasive, easy-to-use and cost effective.
APDW is the one of the most important conferences in the Asia Pacific region for gastrointestinal specialists, with many KOLs present. During the conference, Volition expects to have the opportunity to outline and formalize plans with KOLs for an Asia Pacific wide, multi-center trial to assist with product launches across the region. The event will be held at the Hong Kong Convention and Exhibition Centre, Wan Chai, Hong Kong from September 23rd through September 26th.
Volition will also be hosting a symposium at the TDDW entitled, "A Blood-Based Approach to Detection of Digestive Cancers". Volition's Chief Scientific Officer, Dr. Jake Micallef, will address how Nu.QTM biomarkers have demonstrated positive results in the early detection of digestive cancers. The symposium will be held on September 30th from 12:15 pm CST to 1:35 pm CST, at Conference Room E (202). The conference is being held at the NTUH International Convention Center, Taipei, Taiwan from September 29th through October 1st.
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Day, Volition
+44 (0)7557 774620
Scott Powell, Volition
+1 (646) 650 1351
Tirth Patel, Edison Advisors
+1 (646) 653 7035
Rachel Carroll, Edison Advisors
+44 (0)20 3077 5711
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
SOURCE VolitionRx LtdNEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...